RESEARCH ARTICLE

The cardioprotective and antiarrhythmic effects of *Nardostachys chinensis* in animal and cell experiments

Min Li1,2†, Xue Xu1†, Xinyu Yang1,2, Joey S. W. Kwong3 and Hongcai Shang1,4*

Abstract

**Background:** Cardiovascular disease (CVD) is the leading cause of premature death throughout the world. An estimated 17.5 million people died from CVD in 2012, representing 31% of all global deaths. *Nardostachys chinensis* (NC), a typical traditional Chinese medicine (TCM), plays a crucial role in the management of patients with CVD, especially for those with cardiac arrhythmia. The purpose of this study was to evaluate the cardioprotective and antiarrhythmic effects of NC in animal and cell experiments.

**Methods:** To review the cardioprotective and antiarrhythmic effects of NC, studies of NC on cardiovascular diseases in animal and cell experiments were identified from five databases through April 2016. Two investigators independently conducted the literature search, study selection, and data extraction.

**Results:** A total of 16 studies were identified, including five animal experiments and eleven cell experiments. Four studies showed significant effects of NC on myocardial protection by inhibiting myocardial apoptosis, inflammation and oxidative stress. Twelve studies indicated significant beneficial effects of NC in cardiac arrhythmia primarily through the modulation of ion channels (*I*_K, *I*_K1, *I*_Na, *I*_Ca-L, *I*_to).

**Conclusion:** The above findings showed the possible efficacy of NC via its cardioprotective and antiarrhythmic effects, but the results should be interpreted with caution due to the limitations and the deficiencies in the studies.

**Keywords:** *Nardostachys chinensis*, NC, Cardioprotective effects, Antiarrhythmic effects, Animal experiments, Cell experiments

Background

Cardiovascular disease (CVD) is the leading cause of premature death throughout the world. An estimated 17.5 million people died from CVD in 2012, representing 31% of all global deaths [1]. Cardiac arrhythmias, abnormalities in the heart rate or rhythm, are a form of CVD that affect the pumping function of the heart [2, 3]. The electrophysiological mechanism of cardiac arrhythmia mainly involves two aspects, disorders of impulse conduction (triggered activity, re-entry) and anomalies of electric impulse formation (mostly enhanced automaticity) [4]. Based on these mechanisms, multiple therapeutic measures, such as pharmacological treatment, electric defibrillation, radiofrequency catheter ablation, and artificial cardiac pacing, are extensively developed and employed in the treatment of cardiac arrhythmias [5, 6]. In most cases, pharmacological interventions are the preferred therapeutic method. Unfortunately, almost all western antiarrhythmic drugs are associated with notable adverse effects, and certain agents may even be proarrhythmic [7] as confirmed by the Cardiac Arrhythmia Suppression Trial (CAST) [8]. Due to the limitations of the currently available treatments, complementary and alternative medicine (CAM) is increasingly sought to treat cardiac arrhythmia. Traditional Chinese medicine (TCM), a major type of CAM, has been used in patients with cardiac arrhythmia for thousands of years and remains a popular treatment option in China and worldwide [9]. However,
studies on the mechanisms of TCM in the treatment of cardiac arrhythmia are lacking, and further exploration is greatly needed.

*Nardostachys chinensis* (NC), the rhizomes and roots of *Nardostachys jatamansi DC*, can rectify qi, relieve pain, resolve constraint and fortify the spleen according to TCM theory [10]. NC has a long history of usage as an ethnomedicine and has been used to treat various diseases of different systems, such as indigestion, vomiting, hyperglycaemia, epilepsy, hysteria, and dyslipidaemia [11, 12]. The currently available data suggest the application of NC in CVD, especially in cardiac arrhythmia [13, 14]. Meanwhile, the Chinese patent medicines Wenxin Keli and Shensong Yangxin capsule play crucial roles in the treatment of all types of cardiac arrhythmias, e.g., ventricular premature beat (VPB), atrial fibrillation, and supraventricular arrhythmia [15–17]. However, little is known about the mechanism of NC in CVD from animal and cell experiments. Consequently, we conducted this systematic review to evaluate the cardioprotective and antiarrhythmic effects of NC in animal and cell experiments and provided some clues for researchers to develop new antiarrhythmic drugs based on NC.

**Methods**

**The goal**

The purpose of this study is to evaluate the cardioprotective and antiarrhythmic effects of NC in animal and cell experiments.

**Search methods for the identification of studies**

PubMed, The Cochrane Library, China National Knowledge Infrastructure (CNKI), the Wanfang Database, and the Chinese Scientific Journal Database (VIP) were searched for eligible studies from inception to April 2016. The search strategy used the following general terms: “Nardostachys chinensis”, “Nardostachys chinensis Batal”, “Nardostachys jatamansi DC”, “Nardosinone”, “Nardostachys Radix et Rhizoma”, “Animal”, “Mouse”, “Mice”, “Rat”, “Rabbit”, “Pig”, “Swine”, “Hog”, “Sheep”, “Dog”, “Monkey”, “Cat”, “Ape”, “Homoioidea”, and “cell”.

**Criteria for the consideration of studies for this review**

Studies on the cardiovascular system in animal and cell experiments were considered for inclusion in this review. The intervention was a single medicine, *Nardostachys chinensis*, or its active compounds. Studies on proprietary Chinese medicines and traditional Chinese medicine decoctions were excluded, though NC was one of their main ingredients. We included only journal articles and academic dissertations.

**Data extraction and management**

Two investigators independently conducted the literature search, study selection, and data extraction. The data from the included studies were managed using a pre-standardized extraction form. The extracted data include the study name, the type of experiment, the intervention, the dose, groups, randomness, outcomes and so on. Disagreements were discussed and resolved in a consensus meeting with the corresponding author.

**Assessment of the risk of bias for animal studies**

According to SYRCLE’s risk of bias tool, we assessed the animal studies [18].

**Results**

**Search process**

The initial search using the electronic search strategies yielded 169 studies. After removing 47 duplicates from different databases, we evaluated 122 potentially relevant articles for eligibility. After screening the titles and abstracts, we excluded 101 studies. Of the 21 remaining studies, we further excluded 5 studies after screening the full-text articles. Eventually, we included 16 studies. A flow chart (Fig. 1) illustrates our search process and study selection.

**Included studies**

We included 16 studies in this review [19–34]. Among them, 12 studies were published in Chinese journals, [19, 23, 24, 26–34] and 4 studies were published in English-language journals [20–22, 25]. Five studies were associated with animal experiments [19, 20, 23–25], and 11 studies were related to cell experiments [21, 22, 26–34]. 4 studies reflected the reported cardioprotective effects of NC [19–22], including 2 studies based on cell experiments [19, 20] and 2 studies based on animal experiments [21, 22]. 12 studies showed the antiarrhythmic effects of NC [23–34], including 9 studies based on cell experiments [26–34] and 3 studies based on animal experiments [23–25].

**The cardioprotective effects of NC**

Two cell experiments showed that the active compounds of NC had cardioprotective effects [21, 22]. One intervention used the volatile oil of NC [21], and the other used Nardosinone [22]. They both verified the myocardial protective effect of NC in cultured H9c2 cardiomyocytes. Oxidative stress was a basic cause of cardiovascular diseases [35]. Reactive oxygen species (ROS), the major product of oxidative stress, can lead to cardiomyocyte dysfunction, I/R injury, and heart failure [36]. Tert-butyl hydroperoxide (tBHP) can cause an accumulation of excess intracellular ROS and induce H9c2 cardiomyocyte injury and even death. When H9c2 cells were pre-treated with the volatile oil of NC
before the addition of tBHP, cell survival increased in a dose-dependent manner [21]. A high dose of volatile oil almost fully protected the cells from injury. Under a light microscope, the volatile oil-treated H9c2 cardiomyocytes remained healthy even after a tBHP challenge, and the control cells shrunk. In addition, the volatile oil of NC reduced the ROS level and induced antioxidant response element (ARE) transcriptional activity. The activation of the Akt signalling has been shown to exhibit a cardioprotective effect. The volatile oil of NC can activate the phosphorylation of Akt in H9c2 cardiomyocytes. Simultaneously, the cell protective effects of the volatile oil would weaken and even disappear when an Akt inhibitor was added. Cardiac hypertrophy was an effective and adaptive compensatory response under various stimuli or pressure loads. However, this kind of compensatory response may result in heart failure, cardiac arrhythmia or even sudden death with continuous development [37]. It has been shown that Angiotensin II (Ang II), as a vital mediator, could cause cardiac hypertrophy [38]. Nardosinone, one of main extracts of NC, could significantly inhibit the enlargement of cardiac hypertrophy and myocardial injury. The volatile oil of NC can activate the phosphorylation of Akt in H9c2 cardiomyocytes. Simultaneously, the cell protective effects of the volatile oil would weaken and even disappear when an Akt inhibitor was added. Cardiac hypertrophy was an effective and adaptive compensatory response under various stimuli or pressure loads. However, this kind of compensatory response may result in heart failure, cardiac arrhythmia or even sudden death with continuous development [37]. It has been shown that Angiotensin II (Ang II), as a vital mediator, could cause cardiac hypertrophy [38]. Nardosinone, one of main extracts of NC, could significantly inhibit the enlargement of cardiac hypertrophy and myocardial injury.

The I/R model group underwent ligation and ligation, which was released after 20 min followed by 60 min of reperfusion. The volatile oil of NC was given to the NC group-1 rats 15 min before ligation and to the NC group-2 rats 15 min before reperfusion. Compared with the I/R model group, NC group-1 and NC group-2 showed significantly reduced serum levels of Interleukin-6 (IL-6), Tumour Necrosis Factor (TNF-α), Creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), left ventricular infarction size, and frequency and duration of ventricular arrhythmia.

The antiarrhythmic effect of NC

Nine studies reported the antiarrhythmic effects of the volatile oil and the extract of NC in cell experiments. The antiarrhythmic effect of NC was more significant than that of the control group (Table 1). Acute myocardial infarction (AMI) is a common cardiovascular disease that causes serious damage to human health. The morbidity of AMI increased year by year, becoming a vital public health problem [39, 40]. Currently, one of the most effective therapeutic measures for patients with AMI has been the restoration of the blood supply [41]. However, sudden reperfusion after a relatively long period of ischaemia could result in Ischaemia-Reperfusion (I/R) injury [42]. To moderate this injury, many studies have concentrated on interventions that can protect the heart [43, 44]. The goal of the first animal experiment was to observe the effects of the volatile oil of NC at different time points on myocardial I/R injury in rats [19]. The sham group received ligation but not ligation on the anterior descending coronary artery. The I/R model group underwent ligation and ligation, which was released after 20 min followed by 60 min of reperfusion. The volatile oil of NC was given to the NC group-1 rats 15 min before ligation and to the NC group-2 rats 15 min before reperfusion. Compared with the I/R model group, NC group-1 and NC group-2 showed significantly reduced serum levels of Interleukin-6 (IL-6), Tumour Necrosis Factor (TNF-α), Creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), left ventricular infarction size, and frequency and duration of ventricular arrhythmia.

The I/R model group underwent ligation and ligation, which was released after 20 min followed by 60 min of reperfusion. The volatile oil of NC was given to the NC group-1 rats 15 min before ligation and to the NC group-2 rats 15 min before reperfusion. Compared with the I/R model group, NC group-1 and NC group-2 showed significantly reduced serum levels of Interleukin-6 (IL-6), Tumour Necrosis Factor (TNF-α), Creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), left ventricular infarction size, and frequency and duration of ventricular arrhythmia.

The antiarrhythmic effect of NC

Nine studies reported the antiarrhythmic effects of the volatile oil and the extract of NC in cell experiments. The antiarrhythmic effect of NC was more significant than that of the control group (Table 1). Acute myocardial infarction (AMI) is a common cardiovascular disease that causes serious damage to human health. The morbidity of AMI increased year by year, becoming a vital public health problem [39, 40]. Currently, one of the most effective therapeutic measures for patients with AMI has been the restoration of the blood supply [41]. However, sudden reperfusion after a relatively long period of ischaemia could result in Ischaemia-Reperfusion (I/R) injury [42]. To moderate this injury, many studies have concentrated on interventions that can protect the heart [43, 44]. The goal of the first animal experiment was to observe the effects of the volatile oil of NC at different time points on myocardial I/R injury in rats [19]. The sham group received ligation but not ligation on the anterior descending coronary artery. The I/R model group underwent ligation and ligation, which was released after 20 min followed by 60 min of reperfusion. The volatile oil of NC was given to the NC group-1 rats 15 min before ligation and to the NC group-2 rats 15 min before reperfusion. Compared with the I/R model group, NC group-1 and NC group-2 showed significantly reduced serum levels of Interleukin-6 (IL-6), Tumour Necrosis Factor (TNF-α), Creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), left ventricular infarction size, and frequency and duration of ventricular arrhythmia.

The I/R model group underwent ligation and ligation, which was released after 20 min followed by 60 min of reperfusion. The volatile oil of NC was given to the NC group-1 rats 15 min before ligation and to the NC group-2 rats 15 min before reperfusion. Compared with the I/R model group, NC group-1 and NC group-2 showed significantly reduced serum levels of Interleukin-6 (IL-6), Tumour Necrosis Factor (TNF-α), Creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), left ventricular infarction size, and frequency and duration of ventricular arrhythmia.

The I/R model group underwent ligation and ligation, which was released after 20 min followed by 60 min of reperfusion. The volatile oil of NC was given to the NC group-1 rats 15 min before ligation and to the NC group-2 rats 15 min before reperfusion. Compared with the I/R model group, NC group-1 and NC group-2 showed significantly reduced serum levels of Interleukin-6 (IL-6), Tumour Necrosis Factor (TNF-α), Creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), left ventricular infarction size, and frequency and duration of ventricular arrhythmia.

The I/R model group underwent ligation and ligation, which was released after 20 min followed by 60 min of reperfusion. The volatile oil of NC was given to the NC group-1 rats 15 min before ligation and to the NC group-2 rats 15 min before reperfusion. Compared with the I/R model group, NC group-1 and NC group-2 showed significantly reduced serum levels of Interleukin-6 (IL-6), Tumour Necrosis Factor (TNF-α), Creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), left ventricular infarction size, and frequency and duration of ventricular arrhythmia.

The I/R model group underwent ligation and ligation, which was released after 20 min followed by 60 min of reperfusion. The volatile oil of NC was given to the NC group-1 rats 15 min before ligation and to the NC group-2 rats 15 min before reperfusion. Compared with the I/R model group, NC group-1 and NC group-2 showed significantly reduced serum levels of Interleukin-6 (IL-6), Tumour Necrosis Factor (TNF-α), Creatine kinase-MB (CK-MB), cardiac troponin T (cTnT), left ventricular infarction size, and frequency and duration of ventricular arrhythmia.
with the whole-cell patch-clamp technique [26–34]. The patch-clamp technique is an electrophysiological technique for studying cells, cell membranes, and isolated organelles. All patch-clamp methods depend on a very high-resistance seal between a membrane and a micro-pipette to control the voltage and monitor the currents of ion channels [47]. One study reported a delayed rectifier potassium current (I_k) and an inward rectifier potassium current (I_K1) [26]. Two studies reported an L-type calcium current (I_Ca,L) [27, 28] and a transient outward potassium current (I_to) [29, 31]. The other studies reported on sodium currents (I_Na) [27, 29, 30, 32–34]. The detailed information is given in Table 2.

Six studies with eight groups showed the dose-responses between the active compounds of NC and the inhibition ratio of a current at a fixed voltage [26–31]. Two studies described dose-responses, but no detailed inhibition ratio information was provided [27, 29]. The other four studies with five groups gave detailed descriptions and used the volatile oil of NC as the intervention [26, 28, 30, 31]. The inhibition ratio of the current was closely related to the dose of the volatile oil. Generally, the current inhibition ratio would increase gradually as the dose of the volatile oil increased. Further details are given in Table 3.

Seven studies described the current density and voltage (I-V) curve [26–32]. I-V represented interactions in ion channels and an I-V curve was usually drawn when voltage and current density were taken as the abscissa and the ordinate. Thus, if voltage changed, the current density would also change without any interventions. Compared with a control group, the volatile oil or the extract of NC could decrease current density under the corresponding voltage. However, this decrease in current density was reversible. Generally, the current density of isolated cells would rise and even completely recover when these cells were washed with extracellular fluid.

The activation or inactivation of some ion channels depends on membrane voltage. Four studies reported the activation and inactivation of ion channels through half of the activating voltage (V_1/2) and the slope factor according to the Boltzmann Equation [26, 28, 30, 31]. The volatile oil of NC had a negative effect on the activation of ion channels by acting on membrane voltage and exhibited a positive effect on inactivation. The details are given in Tables 4 and 5.

The Nav1.5-HEK cell has only individual sodium channels, encodes mouse cDNA and is expressed in human embryonic kidney (HEK) cells. Three studies confirmed the antiarrhythmic effects of the volatile oil based on the Nav1.5-HEK cell [32–34]. As the results showed, the volatile oil of NC had an obvious inhibitory effect on sodium membrane potential in a dose-dependent manner. In addition, the volatile oil of NC could accelerate inactivation and inhibit the activation of sodium channels. Current-voltage, conductance-voltage and the current-frequency relationship of the Nav1.5-HEK cell were also affected by the volatile oil of NC.

Three studies reported the antiarrhythmic functions of NC and its active compounds in animal experiments [23–25] (Table 6). In the first study, 0.002% aconitine, 1 mL/kg, was used to treat rats in a model group and a Nardosinone group to establish a tachyarrhythmia animal model [23]. The Nardosinone group was treated by 100 μg/g of nardosinone via intraperitoneal injection and the normal and tachyarrhythmia groups were given the same volume of saline. Compared with the normal group, the model group exhibited significant increases in heart rate (HR), left ventricular end-diastolic pressure (LVEDP), the heart coefficient, Ca²⁺ level, cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). In contrast, the levels of left ventricular systolic pressure (LVSP), +dp/dt_max and -dp/dt_max decreased. Compared with the model group, the above indexes were obviously improved in the Nardosinone group. In addition, the differences in cAMP and PKA between the normal group and the Nardosinone group were subtle.

The goal of the second animal experiment was to investigate the mechanisms of NC on spontaneous ventricular arrhythmias in rats with AMI [24]. Compared with the controls, metoprolol and NC could decrease the ventricular fibrillation (VF) incidence, the cumulative number of premature ventricular contractions (PVCs) and ventricular tachycardias (VTs), and the infarct size of the left ventricular tissue. However, no significant differences were observed in the above indexes between the metoprolol and NC groups. Metoprolol significantly prolonged the P-R interval and decreased the HR and mean arterial pressure (MAP). However, no significant differences were found in the QRS or the Q-T intervals between the control and treatment groups. NC also decreased HR, but it produced no significant changes in MAP, the P-R interval, the QRS interval or the Q-T interval. Compared with NC, metoprolol significantly prolonged the P-R interval. In addition, the results from immunohistochemistry, Western blot, and RT-PCR showed that the protein expression of Connexin 43 (Cx43) in the control group was significantly lower than that in the metoprolol and NC groups.

The third experiment presented the validated functions of the volatile oil of NC on the ventricular effective refractory period (ERP) and compared its therapeutic effects between local infiltration and airway inhalation at different time points [25]. This study showed that the ERP could be remarkably prolonged by the volatile oil of NC and that the best intervention time point was 15–45 min. For the drug delivery methods, airway inhalation was more effective than local infiltration.
Assessment of the risk of bias for animal studies

There were five animal articles in our manuscript [19, 20, 23–25]. According to SYRCLE’s risk of bias tool, we found that the detailed information of the studies was unclear regarding selection bias, performance bias, detection bias, attrition bias, reporting bias and so forth. Only one study [23] mentioned a random number table, and the others did not report the random allocation.
sequence generation methods. In addition, all studies described the completeness of the outcome data for each main outcome, as shown in Table 7.

**Discussion**

NC is a traditional Chinese medicine that has beneficial effects on myocardial protection through the inhibition of myocardial apoptosis, inflammation and oxidative stress [19–22]. It has also been shown to modulate ion channels against cardiac arrhythmias [26–34]. Ion channels represent a class of special hydrophilic protein channels on cytomembranes and one of their important functions is to generate bioelectricity [48, 49]. The movement of ions, such as sodium, potassium, calcium, and chloride, through the myocardial cell membrane forms the basis of electrical activity in myocardial cells. If ion movement across cell membranes is disorderly, cardiac arrhythmias can manifest [50]. Therefore, searching for new effective modalities to regulate ion channels is challenging. Many current studies have focused on interventions that can treat and prevent cardiac arrhythmia.

The generation of myocardial cell action potentials is the basis of cardiac electrical activity, which includes five phases (from 0 to 4) [51]. Depolarization from the SA node brings the membrane potential to the threshold, opening the voltage-gated sodium channels and giving rise to the peak current of Na+ and the rapid upstroke (phase 0) of the cardiac action potential. Inactivation of the sodium channel and activation of Ik are the predominant contributors to the partial membrane repolarization in the first phase. Phase 2, the wavelike plateau, is a long phase due to the delicate balance between the inward currents (mostly ICa-L) and the outward currents (mostly Ik). As the inward currents (ICa-L) become inactivated, the outward currents (Ik) predominate, causing further repolarization and bringing the membrane potential towards the potassium equilibrium potential (phase 3). Then, the membrane potential returns to its resting potential after full repolarization during phase 4, which depends on numerous components such as the Na+–K+ pump, the Na+–Ca2+ exchanger and the Ca2+ pump to recover the normal concentration gradient of the myocardial cell membrane.

The role of Ik1 is to influence the resting potential of the myocardial cell membrane and repolarization (phases 2 and 3) in fast response myocardial cells. The volatile oil of NC can inhibit Ik1 in a concentration-dependent manner and decrease Ik1 density under different voltage regulations in isolated ventricular myocytes in rats [23]. Therefore, NC may depend on a decreased Ik1 to produce its antiarrhythmic effects. Interestingly, a large proportion of antiarrhythmic drugs do not regard Ik1 as a main therapeutic target. The reason may involve two aspects. On one hand, a highly selective Ik1 blocker or agonist is not available. On the other hand, the proarrhythmic or antiarrhythmic effects of Ik1 are not very clear if Ik1 is inhibited or blocked. More evidence is essential to confirm the regulatory mechanism of Ik1 on cardiac arrhythmias.

Ik0, the main current responsible for the early rapid repolarization (phase 1) in fast response cells, has been proven to exist extensively in myocardial cells, especially in atrial and ventricular myocytes in mammals. It has a significant effect on the shape and the duration of the cardiac action potential [52]. In addition, the Ik0 is characterized by a transmural gradient in current density across the ventricular myocardium that leads to significant differences in cardiac action potentials between the

**Table 3** The information of dose-response

| Study               | Type  | Dose       | Number | Half of the activating voltage (mV) Pre-treatment | Half of the activating voltage (mV) Post-treatment | Slope factor Pre-treatment | Slope factor Post-treatment |
|---------------------|-------|------------|--------|--------------------------------------------------|--------------------------------------------------|---------------------------|-----------------------------|
| Xiangyu Li et al. 2013 | Ik    | 5 μg/g     | 6      | 23.65 ± 0.65                                     | 28.19 ± 0.57                                     | 6.09 ± 0.56               | 5.14 ± 0.51                 |
| Ming Cao et al. 2010 | ICa-L | 10 μg/g    | 5      | −5.47 ± 0.50                                     | −2.77 ± 0.49                                     | 4.68 ± 0.39               | 4.50 ± 0.40                 |
| Tao Yang et al. 2009 | INa   | 5 μg/g     | 6      | −4.36 ± 0.98                                     | −4.02 ± 1.01                                     | 5.63 ± 0.75               | 5.03 ± 0.80                 |
| Langjie Hu et al. 2009 | Ito   | 6 μg/g     | 5      | 36.06 ± 1.79                                     | 34.79 ± 3.03                                     | 22.97 ± 1.49              | 30.79 ± 2.90                |

*means P < 0.05
endocardium and the epicardium [53]. This distribution gives rise to repolarization heterogeneity and is probably responsible for the main pathogenesis of ventricular tachycardia and ventricular fibrillation.

$I_k$ is able to mediate repolarization in fast (phase 2, 3) and slow (phase 3) response myocardial cells. In addition, a degenerative $I_k$ partially participates in the spontaneous depolarization (phase 4) of Purkinje cells and sinoatrial node cells [54]. Therefore, $I_k$ is closely related to action potential duration (APD) and the effective refractory period (ERP). If $I_k$ occurs abnormally, the excitability and conductivity of myocardial cells could change. Then, all kinds of cardiac arrhythmias can manifest due to abnormal rhythmicity, reentry and triggered activity.

Na$^+$ channels are widely distributed in myocardial cells in mammals and mediate the excitability and conduction of the heart. There are two sub-types of sodium channels. Voltage-dependent sodium channels ($I_{Na}$), i.e., the fast sodium current, are primarily responsible for depolarization (phase 0) in myocardial action potentials [55]. The slow sodium current channels ($I_{Na-S}$) maintain depolarization (phase 0) in myocardial action potentials. $I_{Na}$ channels are primarily responsible for the main pathogenesis of ventricular tachycardia [57]. Therefore, disorder of the Na$^+$ current can promote the occurrence of cardiac arrhythmia.

There are three types of calcium channels in myocardial cells, i.e., B-type, L-type, and T-type [58]. L-type and T-type calcium channels plays major roles in myocardial electrophysiological activity. The activated L-type calcium channel is capable of generating a slow inward calcium current ($I_{Ca-L}$), which is the ionic basis of ventricular cardiac action potentials during phase 2 [59]. T-type calcium channels mainly exist in cardiac autonomic cells, such as sinoatrial node cells, and are activated to affect the pacemaker activity of the heart through a slow inward calcium current ($I_{Ca-T}$) [60]. An abnormal Ca$^{2+}$ current can easily cause early after depolarization (EAD) and delayed after depolarization (DAD), which contribute to the main pathogenesis of cardiac arrhythmia [61].

Cardiac arrhythmias can be clinically divided into tachycardic arrhythmias and bradycardic arrhythmias. Bradycardiac arrhythmias are treated by pharmacological agents, such as atropine, or by the installation of a temporary or permanent pacemaker to decrease depolarization of Purkinje and sinoatrial node cells, and the Na$^+$ current constitutes a large proportion of all ion currents [57]. Therefore, disorder of the Na$^+$ current can promote the occurrence of cardiac arrhythmia.

### Table 5 The detailed information of the inactivation curve

| Study         | Type | Dose | Number | Half of the activating voltage (mV) | Slope factor |
|---------------|------|------|--------|-----------------------------------|-------------|
|               |      |      |        | Pre-treatment | Post-treatment | Pre-treatment | Post-treatment |
| Xiangyu Li et al. 2013 | $I_k$ | 5 μg/g | 6      | −64.46 ± 1.02 | −82.84 ± 1.27* | 14.40 ± 1.13 | 13.35 ± 1.06* |
| Ming Cao et al. 2010 | $I_{Ca-L}$ | 10 μg/g | 5      | −20.82 ± 0.48 | −29.44 ± 1.03* | 6.16 ± 0.43 | 11.05 ± 0.86* |
| Tao Yang et al. 2009 | $I_{Na}$ | 5 μg/g | 6      | −100.92 ± 0.68 | −111.20 ± 0.86* | 10.33 ± 0.62 | 11.33 ± 0.74* |
| Langjie Hu et al. 2009 | $I_h$ | 6 μg/g | 5      | −33.74 ± 0.48 | −40.54 ± 0.70* | 5.00 ± 0.40 | 8.42 ± 0.62* |

Note the following: * means $P < 0.05$

### Table 6 The detailed information of the animal experiment

| Study         | Species | Weight(g) | Random | Groups | Outcome measure |
|---------------|---------|------------|--------|--------|-----------------|
| Peng Jian et al. 2015 | Wistar rats | 200 ± 20 | Random digits table | The normal group ($n = 20$) | HR; Heart coefficient; LVSP; LVEDP; +dp/dt max; −dp/dt max; cAMP; cAMP; cAMP; PKA |
|                |         | 200 ± 20 |        |        |                 |
| Jing Zhang et al. 2014 | SD rats | 280–310 | Not mentioned | The control group ($n = 24$) | PVCs; VTs; VF $; HR; MAP; P-R interval; QRS interval; Q-T interval; Cx43; Infarct size of the left ventricular |
| Ping Zhou et al. 2007 | Wistar rats | 250 ± 50 | Not mentioned | The control group ($n = 24$) | ERP; ERP/RR |

HR Heart rate; Heart coefficient = Heart weight (mg)/rat weight(g); LVSP Left ventricular systolic pressure; LVEDP Left ventricular end-diastolic pressure, cAMP Cyclic adenosine monophosphate, PKA Protein kinase A, PVCs Premature ventricular contractions, VTs Ventricular tachycardias, MAP Mean arterial pressure; VFs Ventricular fibrillations, Cx43 Connexin 43, ERP Effective refractory period
haemodynamic disturbances [62]. Most antiarrhythmic drugs act as various ion channel or receptor blockers and are mainly used for tachycardic arrhythmias. According to the electrophysiological characteristics of these medications, antiarrhythmic agents can be divided into four categories, i.e., Na+ channel, β-receptor, K+ channel and Ca2+ channel blockers [63].

In terms of the main currents involved in action potentials (I_k, I_to, I_Ca-L, and I_Na), NC and its active compounds could inhibit these currents in a dose-dependent manner and decrease current density under different voltage regulation. In addition, NC and its active compounds not only suppress the activation but also promote the inactivation of ion channels in isolated ventricular myocytes in rats and rabbits. Similar to the mechanisms of some Western antiarrhythmic medicines, NC and its compounds exhibit antiarrhythmic effects by restraining these ion channels or prolonging the ERP.

Conclusion

Nardostachys chinensis has certain cardioprotective and antiarrhythmic effects in animal and cell experiments by inhibiting myocardial apoptosis, the inflammation reaction, and oxidative stress and by modulating several ion channels.

Study limitations

NC is one of the traditional Chinese medicines used for the treatment of cardiac diseases, especially cardiac arrhythmia. The therapeutic mechanism of NC and its active compounds was demonstrated in animal and cell experiments. However, many limitations and deficiencies remain. The details are shown as follows: (i) There are not enough studies to confirm the cardioprotective and antiarrhythmic effects of NC or its active compounds. (ii) The studies mainly involved isolated ventricular myocytes or Nav1.5-HEK cells, and other rhythmic cells, such as sinoatrial node cells and Purkinje cells, were not studied, leading to a lack of information on the mechanism of NC. (iii) The volatile oil and the extract of NC are compounds in NC, so it is necessary to determine the monomer composition to verify the therapeutic targets of NC. (iv) The isolated ventricular myocytes were derived from healthy rats or rabbits. Therefore, whether NC has a beneficial role in myocardial cells in animals exhibiting cardiac arrhythmia remains unclear. (v) Most studies are self-controlled, which may lead to low quality in the literature. (vi) Currently, no research studies have reported the effects of NC on I_Ca,L, I_Na,S or I_f. (vii) The studies show that NC has inhibitory effects on tachycardic arrhythmia. Therefore, whether NC is appropriate for bradycardic arrhythmia remains uncertain.

Future perspectives

Although the above studies focused heavily on the mechanism of NC via cell and animal experiments, there is a lack of information regarding the effects of NC in cardiac diseases at the molecular level. In addition, the occurrence of diseases is due to imbalances in gene expression, so it is crucial to restore balance through a variety of interventions. Further relevant research in genomics, transcriptomics, metabolomics and proteomics would need to be conducted for a better understanding of this mechanism. In addition, pharmacological treatments for cardiac arrhythmia are usually administered orally or intravenously in clinical settings. However, cardiac arrhythmias are often paroxysmal. Oral drugs are slow to treat, and intravenous drugs are typically only used in hospitals. These problems are worth consideration. The volatile oil of NC in the form of a nasal spray may be a viable alternative modality in the treatment of cardiac arrhythmia.

Abbreviations

ALT: Alanine aminotransaminase; AMI: Acute myocardial infarction; Ang II: Angiotensin II; ANP: Atrial natriuretic peptide; APD: Action potential duration; ARE: Antioxidant response element; AST: Aspartate aminotransaminase; BNP: B-type natriuretic peptide; CAM: Complementary and/or alternative medicine; CAMP: Cyclic adenosine monophosphate; CAST: Cardiac Arrhythmia Suppression Trial; CAT: Catalase; CK-MB: Creatine kinase-MB; CPK: Creatine phosphokinase; cTnT: Cardiac troponin T; CVDs: Cardiovascular diseases; Cx43: Connexin 43; DAD: Delayed after depolarization; EAD: Early after depolarization; ERK: Extracellular signal-regulated kinase; ERP: Effective refractory period; GPx: Glutathione peroxidase; GST: Glutathione-S-transferase; G-V: Conductance-voltage relationship; HEK: Human embryonic kidney; HR: Heart rate; iNOS: iNOS; I_Ca-L: L-type calcium current; I_f: Delayed rectifier potassium current; I_K: Inward rectifier potassium current; I_L: Delayed rectifier potassium current; I_Ca,T: L-type calcium current; I_Na: Sodium current; I_TO: Transient outward potassium current; I_V: Current-voltage relationship; LDH: Lactate dehydrogenase; LPO: Lipid peroxide; LVDP: Left ventricular end-diastolic pressure; MAP: Mean arterial pressure; MEK: Mitogen-activated protein kinase;
NC. Nardostachys chinensis; PI3K: Phosphatidylinositol 3-kinase; PKA: Protein kinase A; PVCs: Premature ventricular contractions; RCTs: Randomized controlled trials; ROS: Reactive oxygen species; SOD: Superoxide dismutase; tBHP: Tert-butyl hydroperoxide; TCM: Traditional Chinese medicine; TNF-α: Tumour Necrosis Factor; VFs: Ventricular fibrillations; VPB: Ventricular premature beat; VCs: Ventricular tachycardias; β-MHC: β-myosin heavy chain

Acknowledgements

Not applicable

Availability of the data and materials

The datasets generated and/or analysed during the current study are available in PubMed, The Cochrane Library, China National Knowledge Infrastructure (CNKI), the Wanfang Database, and the Chinese Scientific Journal Database (VIP) repository.

Funding

This study was supported by the project (NSFC 81430098).

Authors’ contributions

ML and XX contributed equally to this paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

All authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Key laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China. 2. Beijing University of Chinese Medicine, Beijing, China. 3. Department of Clinical Epidemiology and Department of Health Policy, National Centre for Child Health and Development, Tokyo, Japan. 4. Institute of Integration of Traditional Chinese and Western Medicine, Guangzhou Medical University, Guangzhou, China.

Received: 11 February 2017 Accepted: 4 August 2017

Published online: 10 August 2017

References

1. Riaz M, Zia-Ul-Haq M, Saad B. The Role of Anthocyanins in Health as Antioxidant, in Bone Health and as Heart Protecting Agents. In: Anthocyanins and Human Health: Biomolecular and Therapeutic Aspects. Springer International Publishing: 2016.

2. Yang B, Benzhi C. Advances in the study of arrhythmogenic mechanisms. Journal of International Pharmaceutical Research. 2010;37(2):81–8.

3. Nattel S, Andrade J, Macle L, Rivard L, Dyrda K, Mondesert B, et al. New pharmacological screening of antiarhythmical fractions from Nardostachys chinensis. Journal of Southwest University for Nationalities- Natural Science Edition. 2008;34(3):504–6.

4. Hua W, Gao RL, Zhao BC, Wang J, Chen XH, Cai C, et al. The Efficacy and Safety of Wenxin Keli in Patients with Frequent Premature Ventricular Contractions: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial. Chin Med J (Engl). 2015;128(19):2557–64.

5. Hu D, Banajis-Martinez H, Burashnikov A, Panama BK, Cordeiro JM, Antzelevitch C. Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli. Experimental and theoretical analysis. Int J Cardiol. 2016;207:326–34.

6. Gu CH, Wu YL, Tian SY, Gao X, Qi X, Jia Z, et al. Effect of shensong yangxin capsule on ventricular premature beat and cardiovascular autonomic nervous function in patients with coronary heart disease. Zhong guo Zhong yi Jiie Za Zhi. 2005;25(9):783–6.

7. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.

8. Yang T, Yuan Y, Xu M, Xiaozia Z, Chuanhuaba B, Xu T. Effects of the volatile oil of Nardostachys chinensis administered at different time points on myocardial ischemia-reperfusion injury in rats. Chinese Journal of Hospital Pharmacy. 2012;32(23):1897–9.

9. Subashini R, Yoshika S, Ganaprapagasam A, Deuki T. Protective effect of Nardostachys jatamansi on oxidative injury and cellular abnormalities during doxorubicin-induced cardiac damage in rats. J Pharm Pharmacol. 2006;58(2):257–62.

10. Mafulwanjiang M, Chen J, Xin G, Gong AG, Miernisha A, Du CY, et al. The volatile oil of Nardostachyos Radix et Rhizoma inhibits the oxidative stress-induced cell injury via reactive oxygen species scavenging and Akt activation in H9c2 cardiomyocytes. J Ethnopharmacol. 2014;153(2):491–8.

11. Meng Du, Kun Huang, Lu Gao, Yang L, Wang WS, Wang B, et al. Nardosinone Protects H9c2 Cardiac Cells from Angiotesin II-induced Hypertrophy. J Huazhong Univ Sci Technol Med Sci. 2013;33(6):822–826.

12. Ping Z. Academic dissertation. The Effects of the Volatile Oil of Gan Song on Effective Refractory Period and value of corrected ERP of Myocardial cells of Rats; 2008;

13. Peng J, Qinghali L, Liuhua F. Experimental study on the inhibitory effect of nardosinone on myocardial cell in rats with tachyarrhythmia. The Chinese Journal of Clinical Pharmacology. 2015;31(22):2240–2.

14. Zhang J, Qiang CC, Li WJ, Liu JJ, Lin XX, Cheng YJ, et al. Effects of Nardostachys chinensis on Spontaneous Ventricular Arrhythmias in Rats With Acute Myocardial Infarction. J Cardiovasc Pharmacol. 2014;64(2):127–33.

15. Yuxiang L, Luo J, Yuzhi G, Wang Y, Shuhua Z, Wu Z. The Effect of the volatile oil of Nardostachys chinensis on L-type Calcium Channel in Isolated Ventricular Myocytes in Rats. Lishizhen Medicine and Materia Medica Research. 2013;24(8):1814–7.

16. Qi Z, Zengrong H, Xiteng S, Wang T, Sheng D. The Effect of the extract of Nardostachys chinensis on Sodium and Calcium Channel in Isolated Ventricular Myocytes in Rats. Chinese Journal of Cardiology. 2004;33(2):267–70.

17. Ming C, Yuzhi G, Lu J, Wang Y, Shuhua Z, Wu Z. Tumour Necrosis Factor; VFs: Ventricular fibrillations; VPB: Ventricular premature beat; VCs: Ventricular tachycardias; β-MHC: β-myosin heavy chain

18. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.

19. Yang T, Yuan Y, Xu M, Xiaozia Z, Chuanhuaba B, Xu T. Effects of the volatile oil of Nardostachys chinensis administered at different time points on myocardial ischemia-reperfusion injury in rats. Chinese Journal of Hospital Pharmacy. 2012;32(23):1897–9.

20. Subashini R, Yoshika S, Ganaprapagasam A, Deuki T. Protective effect of Nardostachys jatamansi on oxidative injury and cellular abnormalities during doxorubicin-induced cardiac damage in rats. J Pharm Pharmacol. 2006;58(2):257–62.

21. Mafulwanjiang M, Chen J, Xin G, Gong AG, Miernisha A, Du CY, et al. The volatile oil of Nardostachyos Radix et Rhizoma inhibits the oxidative stress-induced cell injury via reactive oxygen species scavenging and Akt activation in H9c2 cardiomyocytes. J Ethnopharmacol. 2014;153(2):491–8.

22. Meng Du, Kun Huang, Lu Gao, Yang L, Wang WS, Wang B, et al. Nardosinone Protects H9c2 Cardiac Cells from Angiotesin II-induced Hypertrophy. J Huazhong Univ Sci Technol Med Sci. 2013;33(6):822–826.

23. Ping Z. Academic dissertation. The Effects of the Volatile Oil of Gan Song on Effective Refractory Period and value of corrected ERP of Myocardial cells of Rats; 2008;

24. Peng J, Qinghali L, Liuhua F. Experimental study on the inhibitory effect of nardosinone on myocardial cell in rats with tachyarrhythmia. The Chinese Journal of Clinical Pharmacology. 2015;31(22):2240–2.

25. Zhang J, Qiang CC, Li WJ, Liu JJ, Lin XX, Cheng YJ, et al. Effects of Nardostachys chinensis on Spontaneous Ventricular Arrhythmias in Rats With Acute Myocardial Infarction. J Cardiovasc Pharmacol. 2014;64(2):127–33.

26. Yuxiang L, Luo J, Yuzhi G, Wang Y, Shuhua Z, Wu Z. The Effect of the volatile oil of Nardostachys chinensis on L-type Calcium Channel in Isolated Ventricular Myocytes in Rats. Lishizhen Medicine and Materia Medica Research. 2013;24(8):1814–7.

27. Qi Z, Zengrong H, Xiteng S, Wang T, Sheng D. The Effect of the extract of Nardostachys chinensis on Sodium and Calcium Channel in Isolated Ventricular Myocytes in Rats. Chinese Journal of Cardiology. 2004;33(2):267–70.

28. Ming C, Yuzhi G, Lu J, Wang Y, Shuhua Z, Wu Z. The Effect of the volatile oil of Nardostachys chinensis on L-type Calcium Channel in Isolated Ventricular Myocytes in Rats. Lishizhen Medicine and Materia Medica Research. 2010;21(2):284–5.
